title: Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
source: Yahoo
date: 2025-10-15
url: https://finnhub.io/api/news?id=5523089484dc341bf2e88cbecf16c95ed8cbd9a777edf2d9e5756fd7b3939e15
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
